Mebeverine Milpharm (Mebeverine Hydrochloride)

Mebeverine hydrochloride directly blocks calcium channels in gastrointestinal smooth‑muscle cells, reducing intracellular calcium levels. This inhibition prevents muscle contraction, leading to relaxation of the gut wall and a reduction in spasm‑related pain and discomfort without significant anticholinergic activity.

The appropriate dose of Mebeverine Milpharm is determined by the prescribing clinician based on the individual’s condition, severity of symptoms and overall health. Patients should follow the specific dosing instructions provided by their healthcare professional.

Safety data for mebeverine hydrochloride in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mebeverine differs from many antispasmodics because it does not possess anticholinergic properties, resulting in fewer typical anticholinergic side effects such as dry eyes or urinary retention. Its calcium‑channel blocking mechanism offers effective smooth‑muscle relaxation while maintaining a generally favorable tolerability profile.

Mebeverine Milpharm should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Mebeverine Milpharm is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the specific instructions given by their prescriber to achieve optimal therapeutic effect.

Serious adverse reactions, although rare, include allergic responses such as rash, swelling or breathing difficulty, severe abdominal pain that does not improve, and cardiac arrhythmias. Any of these symptoms should prompt immediate medical attention.

Individuals with known hypersensitivity to mebeverine hydrochloride or any of the tablet’s excipients should avoid the product. Caution is also advised for patients with severe hepatic or renal impairment, and it should be used only under medical supervision in these populations.